ZURICH, October 31, 2013 /PRNewswire/ --
?Completion of patient enrolment in the ongoing Phase 2b clinical trial with CYT003
?Investor syndicate will pay Cytos CHF 6.625 million for achievement of this milestone
?Share capital increase in form of a rights offering to be approved at an extraordinary shareholders’ meeting on November 4, 2013
Help employers find you! Check out all the jobs and post your resume.